Vitiligo Drugs Market, by Drug Class (Calcineurin Inhibitors, Corticosteroids, and Psoralens), by Type (Segmental and Non-segmental), by Route of Administration (Oral and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis 2018 – 2026

  • Published On : Aug 2019 |
  • Pages : 164 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Global Vitiligo Drugs Market – Market Insights

Vitiligo is a skin condition characterized by white patches on the skin. It is also known as skin depigmentation. In skin depigmentation, the skin's pigment-making cells known as melanocytes are lost or destroyed, which result into patches. The patches of affected skin appear white and usually have sharp margins. In most of the cases, the patches emerge on the skin, which is more exposed to sunlight. Although the disease can occur at any age, it is more observed in the mid-twenties. Although the disease does not affect the physical health of a person, it creates concerns about physical appearance and ethical identity of the person. The exact cause of vitiligo is not known. It is mostly observed in people with family history of autoimmune diseases.

The global vitiligo drugs market size was valued at US$ 120.6 million in 2017, and is expected to exhibit a CAGR of 8.4% over the forecast period (2018–2026).

Figure 1. Global Vitiligo Drugs Market Value (US$ Mn), by Region, 2018

Vitiligo Drugs  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Increasing prevalence and incidence of vitiligo is expected to propel the global vitiligo drugs market growth

Vitiligo causes loss of skin color in spots. It can affect the skin on any part of the body, hair, and the inside of the mouth. Treatment for vitiligo can restore the color to the affected spot on the skin. However, it cannot completely prevent skin discoloration. According to the American Academy of Dermatology, 2017, the prevalence of vitiligo is approximately 1% in the U.S. and Europe.

Vitiligo is listed among 24 skin diseases examined in the Burden of Skin Disease report commissioned by the American Academy of Dermatology. Moreover, according to reports published by the American Academy of Dermatology in 2017, over 150,000 patient were treated for vitiligo during 2013 in the U.S. According to a study published in the National Center for Biotechnology Information (NCBI), in October 2017, an estimated 0.5-1% of the global population was diagnosed with vitiligo. Furthermore, in the same year, approximately 8.8% of India’s population and 0.38% of Denmark’s population was diagnosed with vitiligo.

Therefore, increasing worldwide prevalence of vitiligo is expected to aid in growth of the global vitiligo drugs market over the forecast period.

However, availability of advanced technologies and alternative therapies for vitiligo treatment is expected to restrain growth of the vitiligo drugs market during the forecast period. For instance, in October 2018, STRATA Skin Sciences, a manufacturer of innovative products for the treatment of skin conditions, announced the launch of XTRAC S3 308nm Laser at the American Society for Dermatologic Surgery Meeting. The XTRAC S3 308nm Laser is used for the treatment of skin disorders such as psoriasis and vitiligo. The XTRAC laser utilizes therapeutic UVB light for the treatment of affected skin areas without damaging surrounding healthy skin.

Figure 2. Global Vitiligo Drugs Market Share (%), by Drug Class

Vitiligo Drugs  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Increasing number of funding grants to accelerate development of effective treatment for vitiligo is expected to bolster the market growth

Increasing number of initiatives undertaken by various government organizations to develop novel treatments for vitiligo is expected to augment the market growth. For instance, in February 2019, American Skin Association (ASA) announced funding for 18 new grants for skin cancer and disease research. The ASA and its affiliates invested over US$ 50 Mn for the treatment of melanoma, psoriasis, and vitiligo. Moreover, various government organizations are also focused on offering funds to accelerate development of effective treatment options for vitiligo, thereby augmenting the market growth. For instance, the Vitiligo Society in Europe funds research projects with the aim of establishing the real causes of vitiligo as well as developing effective and safe treatments for patients. The Society also supports and closely monitors research initiatives and is supported by a Medical and Scientific Advisory Panel.

Key Players

Key players in the market are focused on adopting acquisition strategies to enhance their market share, which is expected to augment the market growth. For instance, in 2017, Aclaris Therapeutics, Inc. acquired Confluence Life Sciences, Inc., a company focused on development of kinase inhibitors for the treatment of autoimmune disorders such as alopecia areata, vitiligo, and atopic dermatitis.

Major players operating in the global vitiligo drugs market include, Dermavant Sciences, Inc., Incyte Corporation, Aclaris Therapeutics, Inc., Dr. Reddy’s Laboratories Ltd., Bristol - Myers Squibb, Pfizer, Inc., Clinuvel Pharmaceuticals Ltd., Applied Biology, Inc., and Boston Pharmaceuticals.

Vitiligo is classified into two types: segmental and non-segmental. In segmental vitiligo, only one side of body is affected by skin depigmentation. In non-segmental vitiligo, both sides of body are affected by skin depigmentation and the affected area of the skin expands with time. In general, non-segmental vitiligo is more common than segmental vitiligo. Vitiligo drugs market is expected to gain significant growth, owing to increasing research and development activities.

Market Dynamics

Vitiligo drugs market is expected to witness significant growth, owing to development of new therapies for vitiligo. For instance, in February 2018, researchers at Yale University School of Medicine discovered a new therapy for the treatment of vitiligo. The therapy can aid in returning the color of depigmented skin due to vitiligo.

Increasing prevalence of vitiligo in emerging economies is also expected to propel demand for vitiligo drugs. For instance, according to a research published in the National Center for Biotechnology Information (NCBI) in 2017, the prevalence of vitiligo in China was approximately 0.56%. Moreover, major companies are focused on expanding their footprint in emerging economies, especially in Asia Pacific, which is expected to drive the market growth.

However, increasing adoption of alternative treatments such as laser therapies and light therapies are expected to decline the market growth.

Key features of the study:

  • This report provides in-depth analysis of the global vitiligo drugs market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2018–2026), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global vitiligo drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include, Dermavant Sciences, Inc., Incyte Corporation, Aclaris Therapeutics, Inc., Dr. Reddy’s Laboratories Ltd., Bristol - Myers Squibb, Pfizer, Inc., Clinuvel Pharmaceuticals Ltd., Applied Biology, Inc., and Boston Pharmaceuticals
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global vitiligo drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global vitiligo drugs market

Detailed Segmentation:

  • Global Vitiligo Drugs Market, By Drug Class:
    • Calcineurin Inhibitors
    • Corticosteroids
    • Psoralens
  • Global Vitiligo Drugs Market, By Type:
    • Segmental
    • Non-segmental
  • Global Vitiligo Drugs Market, By Route of Administration:
    • Oral
    • Topical
  • Global Vitiligo Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Vitiligo Drugs Market, By Region:
    • North America
      • By Drug Class:
        • Calcineurin Inhibitors
        • Corticosteroids
        • Psoralens
      • By Type:
        • Segmental
        • Non-segmental
      • By Route of Administration:
        • Oral
        • Topical
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Drug Class:
        • Calcineurin Inhibitors
        • Corticosteroids
        • Psoralens
      • By Type:
        • Segmental
        • Non-segmental
      • By Route of Administration:
        • Oral
        • Topical
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Class:
        • Calcineurin Inhibitors
        • Corticosteroids
        • Psoralens
      • By Type:
        • Segmental
        • Non-segmental
      • By Route of Administration:
        • Oral
        • Topical
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class:
        • Calcineurin Inhibitors
        • Corticosteroids
        • Psoralens
      • By Type:
        • Segmental
        • Non-segmental
      • By Route of Administration:
        • Oral
        • Topical
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Class:
        • Calcineurin Inhibitors
        • Corticosteroids
        • Psoralens
      • By Type:
        • Segmental
        • Non-segmental
      • By Route of Administration:
        • Oral
        • Topical
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class:
        • Calcineurin Inhibitors
        • Corticosteroids
        • Psoralens
      • By Type:
        • Segmental
        • Non-segmental
      • By Route of Administration:
        • Oral
        • Topical
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Dermavant Sciences, Inc.*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
  • Incyte Corporation
  • Aclaris Therapeutics, Inc.
  • Reddy’s Laboratories Ltd.
  • Bristol - Myers Squibb
  • Pfizer, Inc.
  • Clinuvel Pharmaceuticals Ltd.
  • Applied Biology, Inc.
  • Boston Pharmaceuticals

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Type
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Regulatory Scenario
    • Reimbursement Scenario
    • Merger and Acquisition Scenario
    • PEST Analysis
    • Epidemiology
  4. Global Vitiligo Drugs Market, By Drug Class, 2016 – 2026, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2016 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Calcineurin Inhibitors
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Corticosteroids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Psoralens
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
  5. Global Vitiligo Drugs Market, By Type, 2016 – 2026, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2016 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Segmental
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Non-segmental
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
  6. Global Vitiligo Drugs Market, By Route of Administration, 2016 – 2026, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2016 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Topical
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
  7. Global Vitiligo Drugs Market, By Distribution Channel, 2016 – 2026, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2016 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
  8. Global Vitiligo Drugs Market, By Region, 2016 – 2026, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2016 and 2026 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2026
    • North America
      • Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 – 2026, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Dermavant Sciences, Inc.*
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Incyte Corporation
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Aclaris Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Dr. Reddy’s Laboratories Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bristol - Myers Squibb
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Clinuvel Pharmaceuticals Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Applied Biology, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Boston Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 45 market data tables and 38 figures on "Vitiligo Drugs Market” - Global forecast to 2026.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.